New Drug Shows Survival Benefit for Advanced Gastric Cancer

Sonesitatug vedotin (Sone-Ve), an anti-CLDN18.2 antibody-drug conjugate, significantly improved overall survival compared to chemotherapy in patients with second-line and later CLDN18.2-positive advanced gastric and gastroesophageal junction cancers. The CLARITY-Gastric01 trial results suggest a promising new precision treatment option for this difficult-to-treat cancer, potentially extending patient lives.